AN2 Therapeutics (ANTX) vs Journey Medical (DERM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Journey Medical (DERM) over the past year, gaining 270.2% versus a loss of 21.2%. AN2 Therapeutics is the larger company by market cap ($173.6 million vs $169.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | DERM |
|---|---|---|
| Share price | $4.60 | $6.02 |
| Market cap | $173.59M | $169.91M |
| 1-day change | -5.15% | +1.18% |
| YTD return | +325.44% | -22.83% |
| 1-year return | +270.23% | -21.19% |
| EPS (TTM) | $-1.05 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $9.56 |
| 52-week low | $1.00 | $4.31 |
| Distance from 52-week high | -36.02% | -37.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +95.65% | +128.41% |
| Average volume | 235.07K | 182.16K |
| Shares outstanding | 37.74M | 22.22M |
| Employees | 21 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed DERM by 291.4 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
ANTX vs DERM FAQ
Which is bigger, AN2 Therapeutics or Journey Medical?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $173.59M compared with $169.91M for Journey Medical (DERM).
Which stock has performed better over the past year, ANTX or DERM?
ANTX returned +270.23% over the past 12 months, compared with -21.19% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Journey Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.